Lead Product(s): Olipudase alfa
Therapeutic Area: Genetic Disease
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
Olipudase alfa is the first and only investigational enzyme replacement therapy in late-stage development for the treatment of ASMD.